Perspectives on psychedelic treatment and research in eating disorders: a web-based questionnaire study of people with eating disorders

Harding, Fiona; Seynaeve, Mathieu; Keeler, Johanna Louise; Himmerich, Hubertus; Treasure, Janet; Kan, Carol

doi:10.31083/j.jin2003059

Cited by 9 publications

(12 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…“I think everybody responds different to all sorts of treatment for eating disorders. I think it is essential to be open minded in regard to treatment” [ 150 ]. Importantly, patients expressed concern over psychedelics regarding safety, therapeutic setting, and trust among medical stakeholders, which they stated could be remedied through a priori education, controlled monitoring, and routine follow-up.…”

Section: Future Perspectives and Directionsmentioning

confidence: 99%

Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions

et al. 2022

View full text Add to dashboard Cite

Eating disorders (EDs) are serious, life-threatening psychiatric conditions associated with physical and psychosocial impairment, as well as high morbidity and mortality. Given the chronic refractory nature of EDs and the paucity of evidence-based treatments, there is a pressing need to identify novel approaches for this population. The noncompetitive N-methyl-D-aspartate receptor (NMDAr) antagonist, ketamine, has recently been approved for treatment-resistant depression, exerting rapid and robust antidepressant effects. It is now being investigated for several new indications, including obsessive–compulsive, post-traumatic, and substance use disorder, and shows transdiagnostic potential for EDs, particularly among clinical nonresponders. Hence, the aim of this review is to examine contemporary findings on the treatment of EDs with ketamine, whether used as a primary, adjunctive, or combination psychopharmacotherapy. Avenues for future research are also discussed. Overall, results are encouraging and point to therapeutic value; however, are limited to case series and reports on anorexia nervosa. Further empirical research is thus needed to explore ketamine efficacy across ED subgroups, establish safety profiles and optimize dosing, and develop theory-driven, targeted treatment strategies at the individual patient level.

show abstract

Section: Future Perspectives and Directionsmentioning

confidence: 99%

Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions

et al. 2022

View full text Add to dashboard Cite

show abstract

“…I think it is essential to be open minded in regards to treatment." [131] Importantly, patients expressed concern over psychedelics regarding safety, therapeutic setting, and trust among medical stakeholders, which they stated could be remedied through a priori education, controlled monitoring, and routine follow-up. Another qualitative study explored participant experiences with ceremonial ayahuasca and conventional therapy for AN and BN (N = 13) [132].…”

Section: Future Perspectives and Directionsmentioning

confidence: 99%

Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions

Ragnhildstveit¹,

Slayton²,

Jackson³

et al. 2022

Preprint

View full text Add to dashboard Cite

Eating disorders (EDs) are serious, life-threatening psychiatric conditions associated with physical and psychosocial impairments, as well as high morbidity and mortality. Given the chronic refractory nature of EDs and the paucity of evidence-based treatments, there is a pressing need to identify novel approaches for this population. The noncompetitive N-methyl-D-aspartate receptor (NMDAr) antagonist, ketamine, has recently been approved for treatment-resistant depression, which exhibits rapid and robust antidepressant effects, particularly among clinical non-responders. It is now being investigated for several new indications, including obsessive-compulsive, post-traumatic, and substance use disorder; and shows transdiagnostic potential for EDs. As such, the aim of this review is to examine contemporary findings on the treatment of EDs with ketamine, whether used as a primary, adjunctive, or combination pharmacotherapy. Avenues for future research are also discussed. Overall, results are encouraging and point to therapeutic value, yet are limited to case series and reports principally on anorexia nervosa. Further empirical work is thus needed to explore and establish ketamine efficacy for EDs, and to inform targeted treatment strategies.

show abstract

“…I think it is essential to be open minded in regards to treatment." [150] Importantly, patients expressed concern over psychedelics regarding safety, therapeutic setting, and trust among medical stakeholders, which they stated could be remedied through a priori education, controlled monitoring, and routine follow-up. Another qualitative study explored participant experiences with ceremonial ayahuasca and conventional therapy for AN and BN (N = 13) [151].…”

Section: Future Perspectives and Directionsmentioning

confidence: 99%

Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions

Ragnhildstveit¹,

Slayton²,

Jackson³

et al. 2022

Preprint

View full text Add to dashboard Cite

Eating disorders (EDs) are serious, life-threatening psychiatric conditions associated with physical and psychosocial impairments, as well as high morbidity and mortality. Given the chronic refractory nature of EDs and the paucity of evidence-based treatments, there is a pressing need to identify novel approaches for this population. The noncompetitive N-methyl-D-aspartate receptor (NMDAr) antagonist, ketamine, has recently been approved for treatment-resistant depression, exerting rapid and robust antidepressant effects. It is now being investigated for several new indications, including obsessive-compulsive, post-traumatic, and substance use disorder; and shows transdiagnostic potential for EDs, particularly among clinical non-responders. As such, the aim of this review is to examine contemporary findings on the treatment of EDs with ketamine, whether used as a primary, adjunctive, or combination psychopharmacotherapy. Avenues for future research are also discussed. Overall, results are encouraging and point to therapeutic value, yet are limited to case series and reports on anorexia nervosa. Further empirical work is thus needed to explore ketamine efficacy across ED subgroups; establish safety profiles and optimize dosing; and develop theory-driven, targeted treatment strategies at the individual patient level.

show abstract

Perspectives on psychedelic treatment and research in eating disorders: a web-based questionnaire study of people with eating disorders

Cited by 9 publications

References 53 publications

Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions

Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions

Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions

Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions

Contact Info

Product

Resources

About